Injection-site burning and stinging in patients with rheumatoid arthritis using injectable biologics

Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis

(2009) Paul Emery et al.   ARTHRITIS AND RHEUMATISM

Impact of Warm Compresses on Local Injection-Site Reactions with Self-Administered Glatiramer Acetate

(2009) Helen Jolly et al.   JOURNAL OF NEUROSCIENCE NURSING

Postmarketing Surveillance of the Safety and Effectiveness of Etanercept in Japan

(2009) T. KOIKE et al.   JOURNAL OF RHEUMATOLOGY

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

(2009) Josef S Smolen et al.   LANCET

Validity and reliability of measurement instruments used in research

(2008) C. L. Kimberlin et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

(2008) J Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Golimumab, a human antibody to tumour necrosis factor   given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

(2008) E C Keystone et al.   ANNALS OF THE RHEUMATIC DISEASES

Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

(2008) Edward Keystone et al.   ARTHRITIS AND RHEUMATISM

Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety

(2008) Alberto Alonso-Ruiz et al.   BMC MUSCULOSKELETAL DISORDERS

Tolerability, adherence, and patient outcomes

(2008) A. P. Ross   NEUROLOGY